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THEORY AND METHODS
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Study objective: International variation in the outcomes of patients with acute coronary syndromes (ACS)
has been well reported. The relative contributions of patient, hospital, and country level factors on clinical
outcomes, however, remain unclear, and thus, was the objective of this study.
Design: Multilevel logistic regression models were developed for death/(re)infarction (MI) at 30 days and
death in one year, with patients (1st level) nested in hospitals (2nd level) and hospitals in countries (3rd
level).
Settings: The GUSTO IV ACS clinical trial was carried out at 458 hospital sites in 24 countries.
Patients: 7800 non-ST segment elevation (NSTE) ACS patients.
Main results: There were substantial variations among countries in the processes and outcomes of care at
30 days, ranging from 5.4% to 50.0% for percutaneous coronary intervention, 4.3% to 21.2% for
coronary artery bypass graft surgery, 5.0% to 13.9% for 30 day death/(re)MI, and 4.9% to 14.8% for one
year mortality. However, the residual inter-country variations in 30 day death/(re)MI and one year
mortality became non-significant and nearly disappeared (p.0.500 for both) after adjusting for key
baseline patient characteristics and hospital factors, which became significant (p,0.01 for both). Patient
level factors accounted for 96%–99% of total variation in these end points, leaving the remaining 1% and
4% of variance attributable to hospital level factors.
Conclusion: The international differences in clinical outcomes in this study of NSTE ACS are primarily
accounted for by the patient level factors, with hospital level factors playing a minor part, and the country
level factors a negligible one. These findings have significant policy and research implications involving
international collaboration and comparisons.
D
isparities in cardiovascular and other health outcomes
across geographical regions are common, and yet not
well understood.1 2 Even after adjustment for baseline
patient characteristics, significant variations in clinical out-
comes often persist in acute coronary syndrome (ACS)
patients.3–9 Although some studies have not shown mortality
differences in either ST segment elevation (STE)10–16 or non-
ST segment elevation (NSTE) ACS patients,17 18 others have
reported better quality of life and mortality outcomes in
countries with high revascularisation rates.3 12 19 Such dis-
parities in outcomes provide incentives to further investigate
the underlying factors, including patient and provider
characteristics, socioeconomic and cultural factors, health-
care practices, and other characteristics of healthcare
systems.
To our knowledge, however, no study has formally
identified and quantified the sources of inter-country
variations in the ACS literature, although some have offered
opinions on this.6 8 20 To gauge the amount of variation in
outcomes among countries attributable to patient compared
with non-patient level factors, we applied multilevel model-
ling techniques that took into account the hierarchical and
correlated nature of healthcare data.21–24 In such data,
findings are generally correlated among patients in the same
subgroup, for instance, those cared for at the same hospital or
in the same country. Thus, conventional, single level analyses
that treat the data as if there were no hierarchical structures
violate the assumption of independence of findings required
for such methods, and result in suboptimal estimation of the
effects of hospital and country level factors.21–24 Moreover,
single level analyses are not designed to assess the
components of variation attributable to individual (patient
level) compared with contextual (hospital and country level)
effects. Thus, our objectives were: (1) to assess the extent of
international differences in patient characteristics, care
processes, and clinical outcomes, and (2) to determine the
extent to which the observed inter-country variations in the
composite of 30 day death or post-admission myocardial
infarction (MI) and one year all cause mortality can be
explained by patient, hospital, and country level factors.
METHODS
Patients and study design
Data from the global utilisation of strategies to open occluded
coronary arteries IV acute coronary syndromes (GUSTO IV
ACS) were used. The details of this trial have been previously
reported.25 26 Briefly, 7800 patients from the 458 participating
hospitals in 24 countries were enrolled between July 1998
and April 2000 (table 1).
Eligible patients were 21 years or older, had at least one
episode of angina lasting five minutes or more within the
preceding 24 hours without persistent ST segment elevation,
and a positive cardiac troponin T or I test (determined using a
Abbreviations: NSTE, non-ST segment elevation; ACS, acute coronary
syndrome; GUSTO IV ACS, global utilisation of strategies to open
occluded coronary arteries IV acute coronary syndromes trial; PCI,
percutaneous coronary intervention; CABG, coronary artery bypass
graft; PCV, proportional change in variance; ICC, intraclass correlation
coefficient; MI, myocardial infaction; STEMI, ST segment elevation
myocardial infarction
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local qualitative or quantitative assay) or at least 0.5 mm
transient or persistent ST segment depression on admission.
They were randomly assigned to one of the three treatment
groups: abciximab therapy for 24 hours (0.25 mg/kg bolus
followed by a 0.125 mg/kg per minute infusion up to 10 mg/kg
for 24 hours), abciximab therapy for 48 hours (same bolus
and infusion for 48 hours), or matching placebo (bolus and
48 hour infusion). Coronary angiography was not to be
performed during or within 12 hours after the completion of
the study agent administration, unless the patient had
recurrent or continuing ischaemia at rest associated with
ischaemic ST/T segment changes that were not responsive to
medical treatment. A clinical end point committee, which
was unaware of treatment assignment, adjudicated all
possible incidences of MI and, when requested by the
Safety and Efficacy Monitoring Committee, also, the cause
of death within 30 days. An independent neurologist
adjudicated all suspected occurrences of stroke and intracra-
nial haemorrhage. The ethics committees of the participating
hospitals approved the protocol, and patients gave informed
consent.
Statistical analysis
The primary end point for the GUSTO IV ACS trial (and for
this study) was 30 day death/(re)MI, and one year mortality
was a secondary end point. Because no treatment effect was
found, the three treatment arms were combined. Biomarkers
and renal function were grouped into tertiles to examine
their relations with the primary end points: troponin T (TnT)
(0.01, 0.01–0.5, and .0.5 mg/l; and C reactive protein (CRP)
(4, 4–10, and .10 mg/l; creatinine clearance (58.4, 58.4–
76.9, and .76.9 ml/min; and the extent of ST segment
depression into,1 (or no ST segment depression), 1–1.5, and
>2 mm. For ease of presenting variation among countries,
we further dichotomised these data after examining their
relations with outcomes, and defined an increased value as
follows: .0.01 mg/l for TnT, >1 mm for ST segment depres-
sion, .58.4 ml/min for creatinine clearance, and .10 mg/l
for CRP. The results were presented in terms of percentages
for categorical variables and medians (interquartile ranges)
for continuous variables.
To assess the relative contributions of patient and non-
patient level factors on outcomes, we began with two level
‘‘null’’ models (that is, without containing any independent
variables), with patients at the first level and countries at the
second. We then developed three level ‘‘null’’ models by
including hospitals as an additional level to further identify
the variance component attributable to the hospital effects,
which has been distributed to both patient and country
effects.28 Thereafter, we developed nested three level models
by successively incorporating patient age, other patient
baseline characteristics, and the country level percutaneous
coronary intervention (PCI) and coronary artery bypass graft
(CABG) rates (as estimated from our dataset). The amount of
variance explained was calculated by the proportional change
in variance (PCV), or the percentage reduction from the
estimated variance in the null model as a result of
incorporating a new factor(s) in the model—that is,
PCV=(V0–V1)/V0, where V0 is the estimate of the initial
(null) variance at the country or hospital level before
adjusting for any compositional or contextual factor in the
model, and V1 was the country or the hospital level residual
variance after adjusting for covariates.23 The proportions of
total variance related to hospital and country factors were
estimated by the intraclass correlation coefficient (ICC) using
the formula V/(V+p2/3), where V=V0 or V1, and p2/3 is the
fixed variance at the patient level as suggested by Snijders
and Bosker.28 Each model parameter was estimated using the
restricted penalised quasilikelihood function in HLM version
6.0 (Lincolnwood, IL, USA) or MLwiN 2.1a (University of
Table 1 Number of study sites and patients and selected baseline patient level factors of each country* participating in the
GUSTO IV ACS trial
Country
Sites
(n)
Patients
(n)
Median
age
Female
(%)
Prior MI
(%)
Diabetes
(%)
TnT
(%)
ST depression
(%)
Creatinine
clearance (%)
CRP
(%)
Enrolment MI
(%)
North America
Canada 31 642 65 31 34 25 46 28 79 59 36
United States 48 462 66 42 33 33 39 36 71 68 34
Western Europe
Austria 8 78 66 33 30 35 81 32 66 36 13
Belgium 9 163 66 33 31 21 74 43 73 24 36
France 15 197 68 27 26 17 71 29 67 24 25
Germany 32 395 68 34 26 25 75 42 75 29 28
Greece 15 259 66 35 26 31 66 49 73 24 20
Ireland 5 40 64 15 40 10 83 23 78 43 23
Italy 29 486 66 34 30 21 76 42 71 27 27
Netherlands 27 570 66 33 26 11 71 43 83 25 31
Portugal 8 88 68 25 23 19 83 38 75 25 36
Spain 11 362 68 29 20 23 74 40 75 29 40
Switzerland 7 38 65 32 29 11 82 43 76 34 34
UK 15 124 64 30 36 16 77 32 76 29 35
Scandinavia
Denmark 12 149 66 28 29 10 80 38 80 35 31
Finland 2 79 66 32 34 18 80 42 79 22 28
Norway 10 91 64 42 23 21 84 26 78 23 31
Sweden 28 544 70 34 31 16 88 31 73 22 33
Eastern Europe
Czech 16 765 69 49 38 31 71 51 66 26 29
Poland 24 1657 65 49 34 17 50 44 81 19 26
Other
Australia 9 118 66 35 27 14 64 40 64 40 40
Israel 13 265 63 26 35 30 78 39 76 34 27
New Zealand 3 54 61 20 33 13 94 26 80 24 43
South Africa 10 144 60 22 17 19 76 34 80 33 41
All countries 387 7800 66 38 31 22 66 40 75 31 28
*The actual number of sites from 458 possible sites that had enrolled at least one patient. CRP, C reactive protein .1110 mg/l; creatinine clearance,58.4 ml/
min; MI, myocardial infarction; ST segment depression >1mm; TnT, troponin T .0.01 mg/l. All missing data were imputed as positive for these indicators.
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London, London, UK), which also provides standard errors
and t tests for fixed effects and x2 tests for random effects.
Each variance estimate was presented with a standard error
and a p value based on the x2 test. All other descriptive
analyses were performed using SPSS version 11.0 (Chicago,
IL, USA).
RESULTS
Variations among countries
The baseline patient characteristics differed significantly
among the 24 countries participating in the study (table 1).
Variation in other aspects of health care such as the use of
evidence based drugs was also noticeable, and except for
calcium channel blockers, their use increased substantially
during hospitalisation (table 2).
The diversity was even greater for invasive procedures at
30 days, and there was a threefold variation in the median
length of hospital stay (table 3).
Differences in outcomes across countries were also
pronounced: 5.0% to 13.9% in 30 day death/(re)MI, 2.5% to
8.0% in 30 day mortality, and 4.9% to 14.8% in one year
mortality (table 3).
Sources of variation in 30 day death/(re)MI and in
one year mortality
Table 4 shows the results of our multilevel analyses for 30 day
death/(re)MI.
A small but significant intercountry variance of 0.036
(p=0.004) was first shown in the two level null model after
factoring out the patient level effects. To further exclude the
hospital level effects that were distributed to both the patient
level and country level effects in the two level model, we
developed a series of three level models that also included the
hospital level factors and showed, first of all, that the
intercountry variance was reduced by 22.7% to 0.028 and
became non-significant (p=0.072) in the null model (model
1). This variance was further reduced and became negligible
(p.0.500) after successively controlling for age, for all
baseline patient characteristics, and then also for country
level PCI and CABG rates (models 2–4), so that these factors
explained nearly all (99.6%) the residual intercountry
variation. In contrast, the estimated interhospital variance
of 0.086 was significant (p=0.003) in the three level null
model, but was only reduced to 0.046 (p=0.032) in the full
model (model 4). The reduction in country level variance is
depicted in ‘‘caterpillar’’ plots for shrunken residuals
(logarithmic odds ratios) before and after adjusting for
baseline patient factors (fig 1A). Similar plots for hospital
level variance are given in figure 1B.
The ICC further shows that 1.09% of the total variation was
related to country factors (with the remaining 98.91% related
to patient factors) based on the two level null model (table 4).
This proportion was reduced in the three level models to
0.82%, 0.36%, 0.03%, and 0.00% in models 1–4, respectively.
By contrast, the intrahospital correlation coefficient was
reduced from 2.53% in the three level null model to 1.38%
in the full, three level model (model 4). Thus, 3.4%
((0.0279+0.0862)/(0.0279 +0.0862+3.29)) of the total var-
iance was situated at the hospital and country level in the
null model (model 1), and as a proportion of the hospital and
country variance, 24.5% (0.0279/(0.0279+0.0862)) and 75.5%
were at the country and the hospital level, respectively. After
adjusting for baseline patient characteristics in model 3,
however, such substantial country level effects were reduced
from 24.5% to 2.6%. The patient factors, in contrast,
accounted for 98.6% of the total variation.
The same multilevel analyses performed for one year
mortality also confirmed that the country level factors, which
was significant in the two level null model, played a
negligible part (0%) in explaining the intercountry variation
in one year mortality according to the three level models:
Table 2 Use of evidence based drugs before and during hospitalisation according to country
Country
Aspirin (%) Clopidogrel (%) ACE inhibitors (%) b blockers (%) Nitrates (%)
Calcium channel
blockers (%)
Before During Before During Before During Before During Before During Before During
North America
Canada 90 98 1 11 27 43 57 86 37 63 29 32
United States 84 96 4 19 28 40 54 83 34 59 26 26
Western Europe
Austria 78 95 1 22 46 49 63 89 32 39 27 26
Belgium 79 94 0 0 17 25 66 87 25 52 23 22
France 52 96 3 10 18 22 66 81 82 82 41 43
Germany 80 99 4 12 44 72 55 81 35 66 24 15
Greece 69 96 0 0 41 51 49 73 41 85 40 36
Ireland 95 75 0 0 28 38 60 63 25 38 25 30
Italy 66 96 0 0 31 47 45 78 26 70 32 38
Netherlands 71 97 0 4 14 23 57 86 21 56 24 41
Portugal 90 100 0 1 38 63 53 89 50 81 30 18
Spain 89 96 1 4 17 32 34 66 44 74 32 50
Switzerland 87 97 0 37 24 40 68 84 24 37 21 21
UK 90 100 0 9 21 27 60 85 43 56 40 42
Scandinavia
Denmark 90 98 0 7 17 21 58 86 34 46 33 38
Finland 100 100 0 4 23 35 95 99 54 77 17 17
Norway 92 96 0 1 10 20 70 96 17 44 24 21
Sweden 87 97 1 15 17 28 81 93 34 51 20 24
Eastern Europe
Czech 81 98 0 0 35 48 53 78 58 79 20 16
Poland 91 98 0 0 48 63 63 84 65 90 25 28
Other
Australia 95 98 2 11 27 38 59 81 42 53 31 40
Israel 84 99 0 0 29 54 54 83 26 57 24 23
New Zealand 100 100 0 0 26 30 67 85 46 44 35 35
South Africa 71 98 0 0 24 30 31 63 28 44 13 23
All countries 84 97 1 5 31 43 58 83 46 61 26 29
ACE inhibitors, angiotension converting enzyme inhibitor.
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97.0% was explained by the patient level factors and the
remaining 3% by hospital level factors (model 4, table 4).
DISCUSSION
International comparisons of population health, the inci-
dence and prevalence of disease, and the impact of healthcare
organisations and interventions on health outcomes are of
great interest.1 2 The proliferation of large international
clinical trials in cardiovascular and other areas of medicine
in the past two decades further stimulated investigation into
the variations in practice patterns and outcomes among
countries and geographical regions. These variations in
health status and treatment outcomes, if real, are of
particular concern, as they raise a host of questions
concerning the efficacy, effectiveness, efficiency, and equity
of the social and healthcare systems as well as the diagnostic
and therapeutic procedures used within and among these
countries and geographical regions. Identifying the sources of
variation in patient outcomes is important, as it may have
enormous implications for the design, analysis, and inter-
pretation of such studies. For example, abciximab was not
shown to be beneficial in the overall GUSTO IV ACS sample
except in North America, where a beneficial effect of a
borderline significance was seen. Nevertheless, the Food and
Drug Administration (FDA) in the USA has not approved
abciximab for frontline medicinal treatment of ACS patients
based on the conventional view that subgroup results are less
reliable.27 Our findings of negligible country effects and of
comparatively small hospital effects on outcomes in the
GUSTO IV ACS trial lend support to the FDA’s decision,
although the reasons for better performance in North
America deserve further investigations.
To our knowledge, however, there has not been a rigorous
study performed to quantify the sources of intercountry
variations in treatment outcomes for ACS patients. In this
paper we showed that patient level factors explained 96%–
99% of total NSTE ACS outcome variations. Similar findings
were obtained in our previous studies of ST segment
elevation myocardial infarction (STEMI)3 29 where significant
variations in 30 day and one year mortality were related
mainly to patient characteristics. However, variation in one
year mortality among countries remained highly significant
for the STEMI sample even after adjusting for baseline
patient characteristics, which was not the case for the NSTE
ACS cohort. Whereas the residual intercountry variation was
explained primarily by the country level life expectancy
among STEMI patients, the patient and hospital level factors
explained that variation in NSTE ACS patients. Such
differences may be related to the finding from these studies
that variation was greater among countries but smaller
among hospitals in STEMI than in NSTE ACS patients, and
that life expectancy as a proxy for the state of the nation’s
health and healthcare system had a greater impact on the
outcomes of STEMI than of NSTE ACS. Further research is
clearly required on this intriguing contrast.
It is noteworthy that our results are in agreement with
those in other NSTE ACS studies.7 17 18 Although significant
international differences persisted in the efficacy and safety
of subcutaneous enoxaparin in non-Q wave coronary events
(ESSENCE) trial,8 that study was based on very small
samples from the outlier countries. Thus, our results were
aligned with those obtained from a Swedish study that used
two level modelling of 30 day mortality after a heart failure,23
which confirmed that variation among hospitals in mortality
after hospitalisation was mainly explained by the differences
in baseline patient characteristics. A recent three level
analysis of AMI patients in Ontario, Canada further showed
that 96.6% of variation in one year mortality was related to
patient level factors, leaving 2.8% and 0.6% to physician and
Table 3 Median length of stay and rates of revascularisation (PCI or CABG) and of (re)-myocardial infarction, and/or death
at 30 days, and death at one year according to country
Country
Median LOS
(days)
30 day
One year
death (%)CABG (%) PCI (%)
Revasculation
(%) (re)MI (%) Death (%)
Death/(re)MI
(%)
North America
Canada 8 14 25 39 8.4 3.7 5.5 8.1
United States 7 21 27 47 12.6 4.5 9.1 10.6
Western Europe
Austria 14 5 10 15 8.5 4.2 5.9 11.9
Belgium 11 21 38 58 6.7 3.1 4.1 8.3
France 11 12 36 48 8.6 4.6 4.6 9.1
Germany 15 13 27 40 9.9 5.8 5.6 8.4
Greece 8 6 5 12 6.9 3.1 3.9 7.3
Ireland 15 10 13 20 5.0 5.0 0.0 10.0
Italy 11 16 25 40 9.9 4.5 6.4 8.6
Netherlands 9 12 21 33 6.7 3.7 3.7 7.0
Portugal 10 10 39 49 13.6 8.0 8.0 14.8
Spain 12 8 22 30 8.0 4.4 4.4 8.0
Switzerland 11 11 50 61 7.9 2.6 7.9 7.9
UK 9 7 19 25 8.1 4.8 4.8 10.5
Scandinavia
Denmark 8 15 18 32 8.7 4.0 5.4 8.1
Finland 9 18 19 35 13.9 2.5 12.7 8.9
Norway 7 10 15 25 6.6 4.4 3.3 7.7
Sweden 8 15 24 39 9.6 2.9 7.9 6.4
Eastern Europe
Czech 11 4 7 11 11.1 5.4 7.2 12.8
Poland 12 5 7 12 5.9 2.5 4.1 6.9
Other
Australia 6 8 40 47 10.3 5.1 6.4 6.4
Israel 9 19 40 58 7.5 3.0 5.7 4.9
New Zealand 5 15 11 26 9.3 7.4 1.9 9.3
South Africa 6 21 26 46 6.9 2.8 4.9 5.6
All countries 10 11 19 30 8.4 3.9 5.5 8.3
CABG, coronary artery bypass graft surgery; LOS, length of stay; PCI, percutaneous coronary intervention; (re)-MI, (re)-myocardial infarction.
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hospital level factors, respectively.21 Similarly, another
Ontario study showed that socioeconomic status, although
a significant predictor of patient level mortality, had a
minimal impact on hospital mortality rates after adjusting for
age, sex, and illness severity30; as well, a study of social
context on heart disease mortality in Texas, USA showed that
95% of the total variance was accounted for by variation at
the individual level, leaving the rest to variations in socio-
economic and ethnic factors at the census tract and the
county level.22
It is also of interest to note that the country level
revascularisation rates played a comparatively minor part in
further reducing variations among hospitals and countries.
Although we also found a negative relation between country
level revascularisation and mortality rates, variation among
countries remained significant after adjusting for the country
level revascularisation rate. It should be noted here that these
findings are contextual in nature, and they in no way imply
that invasive procedures did not influence the outcomes of
ACS at the patient level. To make such an inference is to
commit a so called ecological fallacy, to infer an individual
level relation on the basis of group level associations.31
As in other NSTE ACS studies,5 7–9 18 32 we also found
significant intercountry differences in drug and procedure
use. In particular, in-hospital aspirin use was mandated in
the protocol and given at a high rate across all regions (except
for Irish patients) as recommended by the 2002 ACC/AHA
and ESC guidelines.33 34 The use of other efficacious drugs
such as ACE inhibitors, b blockers, and long acting nitrates
also increased after hospital admission, and their rates were
consistent with those found in other studies.7–9 18 Our finding
of significant variations in practice patterns even within the
context of rigorously designed clinical trials shows that
opportunities exist to increase adherence to practice guide-
lines.
Several limitations of our study should be noted. Firstly,
despite the detailed clinical data that had been collected in
the GUSTO IV ACS trial, specific characteristics of hospitals
(for example, information of on-site interventional facilities)
and physician level data were unavailable.27 35 Secondly, the
GUSTO IV ACS sample may differ from the general
population of patients with ACS, as it was not based on a
representative sample in participating countries. In particu-
lar, coronary angiography was not performed within
12 hours of the completion of study agent infusion, which
is the common practice in most hospitals without interven-
tional facilities in North America and Europe. However, this
is unlikely to change the main findings of our study in view
of other studies also showing the predominance of patient
level factors accounting for clinical outcomes.21 23 Thirdly, we
based our multilevel modelling on a latent variable approach,
which assumed an underlying continuous dependent vari-
able.36 It should be noted that there are other methods of
calculating the intraclass correlations and of summarising
contextual level variances, for example, in terms of the
median odds ratio.28 37 However, the use of measures such as
the median odds ratios37 only confirms the findings of this
study, and hence is not presented in this paper.
Table 4 Analysis of the hospital and country level effects on 30 day death/(re)MI and one year mortality
Variable
Hospital level effects Country level effects
Intrahospital
correlation (%)
Intracountry correlation
(%)Variance (SE, p)% Explained Variance (SE, p)% Explained
30 day death/(re)MI
Two level null model – 0.0361 1.09
(0.024;
p = 0.004)
Three level models
Model 1: null 0.0862 0.0279 22.7 2.53 0.82
(0.046; (0.023;
p = 0.003) p = 0.072)
Model 2: age only 0.0718 16.7 0.0122 56.3 2.13 0.36
(0.044; (0.017;
p = 0.010) p = 0.456)
Model 3: all baseline factors* 0.0419 51.4 0.0011 96.1 1.26 0.03
(0.041; (0.012;
p = 0.014) p.0.500)
Model 4: Baseline+country level
CABG-rate
0.0462 46.4 0.0001 99.6 1.38 0.00
0.039; (0.001;
(p = 0.032) p.0.500)
One year death
Two level null model – 0.0369 1.11
(0.024;
p = 0.005)
Three level models
Model 1: null 0.179 0.0172 46.6 5.13 0.49
(0.058; (0.022;
p = 0.001) p = 0.312)
Model 2: age only 0.170 4.9 0.0068 60.5 4.91 0.20
(0.059; (0.018;
p = 0.002) p.0.500)
Model 3: all baseline factors* 0.124 30.6 0.00002 99.7 3.64 0.00
(0.054; (0.015;
p = 0.014) p.0.500)
Model 4: Baseline+country level
CABG-rate
0.103 42.5 0.00023 99.4 3.03 0.01
(0.050; (0.001;
p = 0.008) p.0.500)
*Adjusted for age, prior myocardial infarction, prior transient ischaemic attacks, prior stroke, prior coronary artery bypass graft surgery, prior use of calcium
channel blockers and b blockers, ST segment depression, troponins T, creatinine clearance, and time to randomisation. Adjusted for country level coronary artery
bypass graft surgery (CABG) rate.
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Notwithstanding these limitations and considerations, our
approach to the analysis of geographical variations has wider
applications.
In conclusion, we found that practice patterns as well as
patient characteristics differ among countries in a large,
contemporary sample of NSTE ACS patients, and that
variations in outcomes were related primarily to patient level
factors and only small but significant proportions were
related to hospital and country level factors. The variation
between countries, which was smaller than that between
hospitals, became negligible after controlling for patient and
hospital effects. Greater attention to collecting data on
hospital and physician characteristics in future NSTE ACS
international studies and clinical trials, in addition to further
exploring and refining patient level data, should provide
insights into patient outcomes and optimising care in all
healthcare settings.
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